Breaking News Instant updates and real-time market news.

DEPO

Depomed

$9.23

-0.24 (-2.53%)

, INSY

Insys Therapeutics

$9.97

-0.03 (-0.30%)

10:29
08/08/17
08/08
10:29
08/08/17
10:29

Analyst says sell Depomed as challenging opioid environment seen persisting

Shares of Depomed (DEPO) are plunging after the company reported weaker than expected second quarter results and lowered its guidance. Reacting to the announcement, Janney Capital and Morgan Stanley downgraded the stock to Neutral and Underweight, respectively. RESULTS: Last night, Depomed reported second quarter earnings per share of 8c, which was below consensus of 9c, and announced revenue of $100M for the quarter, beating the expected $99.42M. The company also said it sees 2017 revenue of $400M-$415M, compared to consensus of $418M and the company's prior view of $410M-$430M issued in May. MOVING TO THE SIDELINES: In a post-earnings note to investors, Janney Capital analyst Ken Trbovich downgraded Depomed to Neutral from Buy after another "disappointment." While the company had pre-released second quarter results just weeks ago and had reaffirmed its full year guidance, Depomed surprised by lowering its full-year outlook for revenues and raising its expense guidance, the analyst pointed out. Trbovich noted that the revised guidance seems to be an admission that the challenges facing its business are far greater to overcome than fixing the sales force realignment implemented by the prior CEO. Further, the analyst argued that the new CEO's hope for demonstrating separation for negative industry trends for opioids by year-end has been replaced by the possibility it happens sometime next year. He also cut his fair value estimate on the stock to $8 from $18. SELL DEPOMED: Meanwhile, Morgan Stanley analyst David Risinger downgraded Depomed this morning to Underweight, a sell-equivalent rating, as he fears it will continue to underperform given pressures on the company's number one franchise, Nucynta, an opioid for pain. The analyst pointed out that opioid prescription market declines are driving lower Nucynta sales than expected, even though it has gained some market share. Government officials have been voicing increasing concerns about the opioid crisis in America, and they are intent on driving use down, Risinger said, adding that it appears that Nucynta will continue to be under pressure. Moreover, the analyst highlighted that IMS prescription market trends indicate that short-acting opioids are declining 8% year over year and long-acting opioids are declining 11% year over year. While saying it is unclear if new management appointed earlier this year and the company's board can unlock value, Risinger noted he learned that activist board member Gavin Molinelli of Starboard will shift from the Board Member seat he assumed in March 2017 to "Board Observer" on August 15. He also lowered his price target on Depomed's shares to $5 from $12. OPIOID ENVIRONMENT: On June 8, Depomed and Insys Therapeutics (INSY) were under pressure after the Food and Drug Administration requested that Endo Pharmaceuticals (ENDP) remove its opioid pain medication, reformulated Opana ER, from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks, the FDA stated. This was the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. PRICE ACTION: In morning trading, shares of Depomed have dropped $3.01, or 32.5%, to $6.22.

DEPO

Depomed

$9.23

-0.24 (-2.53%)

INSY

Insys Therapeutics

$9.97

-0.03 (-0.30%)

ENDP

Endo

$9.31

-0.07 (-0.75%)

  • 08

    Aug

DEPO Depomed
$9.23

-0.24 (-2.53%)

08/08/17
JANY
08/08/17
DOWNGRADE
JANY
Neutral
Depomed downgraded to Neutral from Buy at Janney Capital
08/08/17
08/08/17
DOWNGRADE
Target $8

Neutral
Depomed downgraded to Neutral after another guidance cut at Janney Capital
As previously reported, Janney Capital analyst Ken Trbovich downgraded Depomed to Neutral from Buy, saying he reads the company's surprising lowering of its full-year guidance for revenues and raising of its expense guidance as an admission that the challenges facing its business are far greater to overcome than just fixing its sales force alignment. Trbovich, who noted that this was the fifth time in the past six quarters that Depomed has lowered the upper end of its revenue view, cut his fair value estimate on the stock to $8 from $18.
08/08/17
MSCO
08/08/17
DOWNGRADE
MSCO
Underweight
Depomed downgraded to Underweight from Equal Weight at Morgan Stanley
08/08/17
08/08/17
DOWNGRADE
Target $5

Underweight
Depomed downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley downgraded Depomed to Underweight and slashed its price target to $5 from $12. Analyst David Risinger believes pressures on Nucynta, an opiod for pain, will continue to persist as prescriptions decline.
INSY Insys Therapeutics
$9.97

-0.03 (-0.30%)

03/24/17
JANY
03/24/17
NO CHANGE
Target $19
JANY
Buy
Janney says Insys receipt of DEA decision removes 'stonewalling' fear
Janney Capital analyst Ken Trbovich said Insys Therapeutics' receipt of DEA scheduling of Syndros sets up a launch in the second half of the year, giving its sales reps a second product to promote and the company an opportunity to return to growth. Furthermore, the decision removes uncertainty about whether the company's ongoing DOJ investigation led to "stonewalling" of the company's regulatory efforts, noting that "while slow," both the DEA and FDA eventually took action. He keeps a Buy rating and $19 fair value estimate on Insys shares.
07/21/17
JANY
07/21/17
NO CHANGE
Target $16
JANY
Buy
Subsys ANDA somewhat negative for Insys, but not unexpected, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.
05/10/17
PIPR
05/10/17
DOWNGRADE
Target $10
PIPR
Neutral
Insys Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Neutral following the Q1 results and halved his price target for the shares to $10 from $20. Prescription trends for Subsys have been consistently weak and will remain so given the scrutiny of the opioid space and Insys in particular, Amsellem tells investors in a post-earnings research note.
04/06/17
OPCO
04/06/17
NO CHANGE
OPCO
Perform
DoJ settlement not 'end all, be all' for Insys Therapeutics, says Oppenheimer
Oppenheimer analyst Derek Archila thinks Insys Therapeutics' shares are likely to react favorably on an announcement of a DoJ settlement, but he does not view it as the "end all, be all" clearing event for the company as he continues to worry about deteriorating Subsys sales and consensus forecasts for Syndros that look too high. The analyst reiterates a Perform rating on the shares.
ENDP Endo
$9.31

-0.07 (-0.75%)

06/09/17
WBLR
06/09/17
NO CHANGE
WBLR
FDA action on Opana a positive for Collegium, says William Blair
William Blair analyst Tim Lugo views FDA request to remove Endo's (ENDP) Opana ER from the market as a positive for Collegium Pharmaceutical (COLL). The analyst believes Collegium's Xtampza ER has a "best-in-class abuse-deterrent profile." He thinks the drug's scripts could "meaningfully ramp up in the near term." Lugo keeps an Outperform rating on Collegium.
06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/16/17
CANT
06/16/17
INITIATION
Target $12
CANT
Neutral
Endo initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Endo International with a Neutral rating and $12 price target.
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

FLXN

Flexion

$27.40

0.63 (2.35%)

, ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

19:21
06/19/18
06/19
19:21
06/19/18
19:21
Recommendations
Flexion, Anika Therapeutics analyst commentary  »

Flexion to benefit from…

FLXN

Flexion

$27.40

0.63 (2.35%)

ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ENSG

Ensign Group

$38.55

0.06 (0.16%)

19:07
06/19/18
06/19
19:07
06/19/18
19:07
Hot Stocks
Ensign Group subsidiary acquires office building in San Juan Capistrano »

The Ensign Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNOV

MediciNova

$8.37

-0.03 (-0.36%)

19:01
06/19/18
06/19
19:01
06/19/18
19:01
Hot Stocks
MediciNova receives Notice of Allowance from JPO for new patent covering MN-001 »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

19:00
06/19/18
06/19
19:00
06/19/18
19:00
Hot Stocks
USMC awards BAE Systems $198M amphibious combat vehicle contract »

The U.S. Marine Corps has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

18:59
06/19/18
06/19
18:59
06/19/18
18:59
Periodicals
Goldman plans to invest $500M in women-run companies, Reuters says »

Goldman Sachs intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

NTIP

Network-1 Technologies

$3.00

(0.00%)

, SYNA

Synaptics

$48.81

-0.35 (-0.71%)

18:50
06/19/18
06/19
18:50
06/19/18
18:50
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Network-1…

NTIP

Network-1 Technologies

$3.00

(0.00%)

SYNA

Synaptics

$48.81

-0.35 (-0.71%)

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

PRTA

Prothena

$14.99

0.43 (2.95%)

LZB

La-Z-Boy

$33.25

0.1 (0.30%)

ORCL

Oracle

$46.29

-0.25 (-0.54%)

FDX

FedEx

$258.35

-5.295 (-2.01%)

ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

KIN

Kindred Biosciences

$10.00

-0.55 (-5.21%)

SBUX

Starbucks

$57.43

0.22 (0.38%)

GE

General Electric

$12.96

-0.24 (-1.82%)

VALE

Vale

$12.97

-0.21 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 22

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

  • 20

    Sep

  • 21

    Sep

  • 20

    Jun

SD

SandRidge Energy

$17.03

1.21 (7.65%)

, IEP

Icahn Enterprises

$72.11

-0.62 (-0.85%)

18:44
06/19/18
06/19
18:44
06/19/18
18:44
Hot Stocks
SandRidge Energy reaches pact with Icahn Capital on board composition »

SandRidge Energy (SD)…

SD

SandRidge Energy

$17.03

1.21 (7.65%)

IEP

Icahn Enterprises

$72.11

-0.62 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$106.20

-0.85 (-0.79%)

18:32
06/19/18
06/19
18:32
06/19/18
18:32
Hot Stocks
Disney names Jennifer lee Walt Disney Animation Studios CCO »

Disney announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.20

0.05 (0.81%)

18:32
06/19/18
06/19
18:32
06/19/18
18:32
Syndicate
Trillium Therapeutics announces 'at-the-market' issuance program »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.39

0.19 (0.59%)

, GOOG

Alphabet

$1,167.86

-5.77 (-0.49%)

18:17
06/19/18
06/19
18:17
06/19/18
18:17
Periodicals
AT&T in discussions to purchase AppNexus, Cheddar reports »

AT&T (T) is in talks…

T

AT&T

$32.39

0.19 (0.59%)

GOOG

Alphabet

$1,167.86

-5.77 (-0.49%)

GOOGL

Alphabet Class A

$1,178.29

-5.69 (-0.48%)

FB

Facebook

$197.46

-0.84 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Oct

AAL

American Airlines

$41.51

-0.93 (-2.19%)

18:14
06/19/18
06/19
18:14
06/19/18
18:14
Periodicals
Breaking Periodicals news story on American Airlines »

American Airlines offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZN

Zion Oil & Gas

$3.13

(0.00%)

18:13
06/19/18
06/19
18:13
06/19/18
18:13
Hot Stocks
Zion Oil & Gas to start operations at Megiddo-Jezreel #1 as soon as June 21 »

Zion Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.43

0.22 (0.38%)

18:10
06/19/18
06/19
18:10
06/19/18
18:10
Hot Stocks
Starbucks says China third party delivery 'was not a good experience' »

Comments taken from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

EQH

AXA Equitable

$20.94

-0.01 (-0.05%)

18:07
06/19/18
06/19
18:07
06/19/18
18:07
Hot Stocks
Breaking Hot Stocks news story on AXA Equitable »

AXA Equitable reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EQH

AXA Equitable

$20.94

-0.01 (-0.05%)

18:06
06/19/18
06/19
18:06
06/19/18
18:06
Earnings
AXA Equitable reports Q1 non-GAAP EPS 83c, consensus 82c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BAESY

BAE Systems

$0.00

(0.00%)

18:06
06/19/18
06/19
18:06
06/19/18
18:06
Periodicals
USMC awards BAE contract to deliver new amphibious vehicles, Reuters says »

The U.S. Marine Corp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNI

ATN International

$55.30

0.57 (1.04%)

18:04
06/19/18
06/19
18:04
06/19/18
18:04
Hot Stocks
ATN International acquires Geoverse LLC, terms not disclosed »

Geoverse, LLC, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

, GE

General Electric

$12.96

-0.24 (-1.82%)

18:01
06/19/18
06/19
18:01
06/19/18
18:01
Hot Stocks
Walgreens Boots Alliance to replace General Electric in DJIA at open on 6/26 »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

GE

General Electric

$12.96

-0.24 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HPE

HP Enterprise

$15.90

-0.02 (-0.13%)

18:01
06/19/18
06/19
18:01
06/19/18
18:01
Hot Stocks
HP Enterprise to invest $4B in Intelligent Edge technologies »

Hewlett Packard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SBUX

Starbucks

$57.43

0.22 (0.38%)

, NSRGY

Nestle

$0.00

(0.00%)

17:59
06/19/18
06/19
17:59
06/19/18
17:59
Hot Stocks
Starbucks slips after announcing more store closures, cutting Q3 SSS view »

Shares of Starbucks…

SBUX

Starbucks

$57.43

0.22 (0.38%)

NSRGY

Nestle

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

BX

Blackstone

$32.72

-0.31 (-0.94%)

, GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

17:56
06/19/18
06/19
17:56
06/19/18
17:56
Hot Stocks
Blackstone to acquire PSAV »

PSAV announced that it…

BX

Blackstone

$32.72

-0.31 (-0.94%)

GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

SBUX

Starbucks

$57.43

0.22 (0.38%)

17:42
06/19/18
06/19
17:42
06/19/18
17:42
Recommendations
Starbucks analyst commentary  »

Starbucks has no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

ORCL

Oracle

$46.29

-0.25 (-0.54%)

17:36
06/19/18
06/19
17:36
06/19/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle reverses, now down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ORCL

Oracle

$46.29

-0.25 (-0.54%)

17:32
06/19/18
06/19
17:32
06/19/18
17:32
Earnings
Oracle sees Q1 adjusted EPS 67c-69c in USD, consensus 72c »

Sees Q1 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

, GE

General Electric

$12.96

-0.24 (-1.82%)

17:32
06/19/18
06/19
17:32
06/19/18
17:32
Hot Stocks
Walgreens Boots Alliance to replace General Electric in DJIA »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

GE

General Electric

$12.96

-0.24 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.